» Authors » Lockwood Taylor

Lockwood Taylor

Explore the profile of Lockwood Taylor including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 57
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cottu P, Ramsey S, Sola-Morales O, Spears P, Taylor L
Breast . 2021 Dec; 61:118-122. PMID: 34959093
Among stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of...
2.
Pocobelli G, Dublin S, Bobb J, Albertson-Junkans L, Andrade S, Cheetham T, et al.
Pharmacoepidemiol Drug Saf . 2021 Jun; 30(11):1541-1550. PMID: 34169607
Purpose: To estimate prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014. Methods: We conducted a cohort study of singleton live birth deliveries. Maternal characteristics...
3.
Cheetham T, Dublin S, Pocobelli G, Bobb J, Andrade S, Hechter R, et al.
Pharmacoepidemiol Drug Saf . 2020 Sep; 29(11):1489-1493. PMID: 32929845
Purpose: The use of validated criteria to identify birth defects in electronic healthcare databases can avoid the cost and time-intensive efforts required to conduct chart reviews to confirm outcomes. This...
4.
Zhang M, Falconer M, Taylor L
Pharmacoepidemiol Drug Saf . 2020 May; 29(8):958-961. PMID: 32406104
Purpose: Epidemiologic studies consistently report an increased risk of aortic aneurysm (AA) among users of fluoroquinolones (FQ), but confounding by smoking could explain all or some of the observed risk....
5.
Bird S, Toh S, Sahin L, Andrade S, Gelperin K, Taylor L, et al.
Am J Epidemiol . 2018 Oct; 188(2):418-425. PMID: 30321259
Letrozole is an aromatase inhibitor that has an unapproved use for ovulation induction with infertility. Because of the proximity of this use to conception, we selected letrozole to study the...
6.
Freeman M, Farchione T, Yao L, Sahin L, Taylor L, Huybrechts K, et al.
J Clin Psychiatry . 2018 Aug; 79(4). PMID: 30153401
Pregnancy labeling of prescription medications in the US is in the midst of a major transformation. The FDA's previous system, which used letter ratings to convey drug safety, was simple...
7.
Mosholder A, Taylor L, Mannheim G, Ortendahl L, Woodworth T, Toh S
J Clin Psychopharmacol . 2018 Aug; 38(5):505-508. PMID: 30102629
Purpose/background: Stimulant abuse is associated with cardiomyopathy, but cardiomyopathy rates with therapeutic use of stimulants for attention-deficit/hyperactivity disorder (ADHD) are poorly characterized. Labels for methylphenidate, amphetamine, and atomoxetine caution against...
8.
Illoh O, Toh S, Andrade S, Hampp C, Sahin L, Gelperin K, et al.
Pharmacoepidemiol Drug Saf . 2018 Mar; 27(6):604-611. PMID: 29516585
Purpose: To describe the utilization of drugs with pregnancy exposure registries by trimester during pregnancy, in comparison with matched nonpregnant episodes and a pre-pregnancy period. Methods: We identified live-born deliveries...
9.
Bird S, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade S, et al.
Drug Saf . 2017 Aug; 41(1):87-94. PMID: 28840499
Introduction: Pregnancy registries and spontaneous reports are essential pharmacovigilance tools to evaluate drug safety during pregnancy. Objectives: The aim of this study was to evaluate postmarket capture of exposed pregnancies....
10.
Gelperin K, Hammad H, Leishear K, Bird S, Taylor L, Hampp C, et al.
Pharmacoepidemiol Drug Saf . 2016 Dec; 26(2):208-214. PMID: 28028914
Purpose: Our study sought to systematically evaluate protocol-specified study methodology in prospective pregnancy exposure registries including pre-specified pregnancy outcomes, power calculations for sample size, and comparator group selection. Methods: U.S....